The stock of Immunocore Holdings plc ADR (IMCR) has seen a -6.29% decrease in the past week, with a 24.80% gain in the past month, and a 26.03% flourish in the past quarter. The volatility ratio for the week is 1.49%, and the volatility levels for the past 30 days are at 3.54% for IMCR. The simple moving average for the last 20 days is 3.96% for IMCR stock, with a simple moving average of 14.24% for the last 200 days.
Is It Worth Investing in Immunocore Holdings plc ADR (NASDAQ: IMCR) Right Now?
The stock has a 36-month beta value of 0.83. Opinions on the stock are mixed, with 8 analysts rating it as a “buy,” 5 as “overweight,” 3 as “hold,” and 1 as “sell.”
The public float for IMCR is 48.62M, and at present, short sellers hold a 16.48% of that float. On June 13, 2025, the average trading volume of IMCR was 416.37K shares.
IMCR) stock’s latest price update
The stock price of Immunocore Holdings plc ADR (NASDAQ: IMCR) has surged by 0.20 when compared to previous closing price of 35.56, but the company has seen a -6.29% decline in its stock price over the last five trading sessions. zacks.com reported 2025-06-02 that The average of price targets set by Wall Street analysts indicates a potential upside of 65.2% in Immunocore (IMCR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Analysts’ Opinion of IMCR
Many brokerage firms have already submitted their reports for IMCR stocks, with Deutsche Bank repeating the rating for IMCR by listing it as a “Buy.” The predicted price for IMCR in the upcoming period, according to Deutsche Bank is $65 based on the research report published on May 27, 2025 of the current year 2025.
Morgan Stanley, on the other hand, stated in their research note that they expect to see IMCR reach a price target of $35, previously predicting the price at $74. The rating they have provided for IMCR stocks is “Equal-Weight” according to the report published on December 13th, 2024.
Mizuho gave a rating of “Neutral” to IMCR, setting the target price at $38 in the report published on November 11th of the previous year.
IMCR Trading at 15.33% from the 50-Day Moving Average
After a stumble in the market that brought IMCR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -15.34% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at IMCR starting from BAKER BROS. ADVISORS LP, who purchase 807,338 shares at the price of $29.72 back on Mar 17 ’25. After this action, BAKER BROS. ADVISORS LP now owns 2,144,060 shares of Immunocore Holdings plc ADR, valued at $23,993,224 using the latest closing price.
Brian Di Donato, the affiliate of Immunocore Holdings plc ADR, proposed sale 100,000 shares at $30.00 during a trade that took place back on Mar 17 ’25, which means that Brian Di Donato is holding shares at $3,000,000 based on the most recent closing price.
Stock Fundamentals for IMCR
Current profitability levels for the company are sitting at:
- -0.14 for the present operating margin
- 0.99 for the gross margin
The net margin for Immunocore Holdings plc ADR stands at -0.06. The total capital return value is set at -0.05. Equity return is now at value -5.78, with -2.11 for asset returns.
Based on Immunocore Holdings plc ADR (IMCR), the company’s capital structure generated 0.1 points at debt to capital in total, while cash flow to debt ratio is standing at 0.73. The debt to equity ratio resting at 0.11. The interest coverage ratio of the stock is -4.14.
Currently, EBITDA for the company is -70.46 million with net debt to EBITDA at 9.74. When we switch over and look at the enterprise to sales, we see a ratio of 4.06. The receivables turnover for the company is 5.29for trailing twelve months and the total asset turnover is 0.32. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.36.
Conclusion
To sum up, Immunocore Holdings plc ADR (IMCR) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
